Endometrial cancer.

[1]  E. Sala,et al.  The revised FIGO staging system for uterine malignancies: implications for MR imaging. , 2012, Radiographics : a review publication of the Radiological Society of North America, Inc.

[2]  J. Long,et al.  Genetic polymorphisms in obesity‐related genes and endometrial cancer risk , 2012, Cancer.

[3]  H. Putter,et al.  Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. , 2012, European journal of cancer.

[4]  Shuji Ogino,et al.  Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. , 2012, Cancer research.

[5]  P. Pollock,et al.  FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features , 2012, PloS one.

[6]  Ngai Na Co,et al.  Understanding obesity and endometrial cancer risk: opportunities for prevention. , 2011, American journal of obstetrics and gynecology.

[7]  J. Long,et al.  Association of obesity-related genetic variants with endometrial cancer risk: a report from the Shanghai Endometrial Cancer Genetics Study. , 2011, American journal of epidemiology.

[8]  Meenakshi Singh,et al.  Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial. , 2011, Gynecologic oncology.

[9]  K. Leslie,et al.  A Mechanism for Synergy with Combined mTOR and PI3 Kinase Inhibitors , 2011, PloS one.

[10]  K. Thiel,et al.  Endometrial cancer: reviving progesterone therapy in the molecular age. , 2011, Discovery medicine.

[11]  H. Mackay,et al.  Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Z. Langmár,et al.  [Uterine papillary serous carcinoma]. , 2011, Orvosi hetilap.

[13]  K. Leslie,et al.  Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Thiel,et al.  Progesterone: the ultimate endometrial tumor suppressor , 2011, Trends in Endocrinology & Metabolism.

[15]  A. Covens,et al.  Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study. , 2011, Gynecologic oncology.

[16]  H. Itamochi.  Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. , 2010, World journal of biological chemistry.

[17]  K. Lee,et al.  Concurrent endometrial carcinoma following hysterectomy for atypical endometrial hyperplasia. , 2010, European journal of obstetrics, gynecology, and reproductive biology.

[18]  T. Okai,et al.  Genetics of Endometrial Cancers , 2010, Obstetrics and gynecology international.

[19]  H. Putter,et al.  Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial , 2010, The Lancet.

[20]  M. Dimopoulos,et al.  Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy? , 2010, Obstetrics and gynecology international.

[21]  S. Pecorelli.  Corrigendum to “Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium” , 2010 .

[22]  D. Mutch.  The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas , 2009 .

[23]  A. Lau,et al.  Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. , 2009, Cancer research.

[24]  E. Eisenhauer,et al.  Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Meenakshi Singh,et al.  Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. , 2007, Gynecologic oncology.

[26]  Duan Ma,et al.  Down-regulation of the progesterone receptor by the methylation of progesterone receptor gene in endometrial cancer cells. , 2007, Cancer genetics and cytogenetics.

[27]  E. Eisenhauer,et al.  Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer-NCIC IND 160. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Barakat,et al.  Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study , 2006, International Journal of Gynecologic Cancer.

[29]  R. Zaino,et al.  Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia , 2006, Cancer.

[30]  A. Jubb,et al.  Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  T. Wright,et al.  Prevalence of Underlying Adenocarcinoma in Women with Atypical Endometrial Hyperplasia , 2005, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[32]  N. Eberhardt,et al.  Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. , 2005, Gynecologic oncology.

[33]  H. Andersson,et al.  Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel , 2005 .

[34]  K. Leslie,et al.  TYROSINE KINASE INHIBITORS IN ENDOMETRIAL CANCER: 0020 , 2005, International Journal of Gynecologic Cancer.

[35]  E. Eisenhauer,et al.  The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers – a study of the National Cancer Institute of Canada Clinical Trials Group , 2004, International Journal of Gynecologic Cancer.

[36]  K. Swenerton,et al.  Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  K. Leslie,et al.  Molecular tools to reestablish progestin control of endometrial cancer cell proliferation. , 2001, American journal of obstetrics and gynecology.

[38]  M. Brady,et al.  Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Joan L. Walker,et al.  A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. , 2000, Gynecologic oncology.

[40]  C. Eng,et al.  Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. , 2000, Journal of the National Cancer Institute.

[41]  I. Ali.  Gatekeeper for endometrium: the PTEN tumor suppressor gene. , 2000, Journal of the National Cancer Institute.

[42]  D. Coppola,et al.  Immunohistochemical Profile of Endometrial Adenocarcinoma: A Study of 61 Cases and Review of the Literature , 2000, Modern Pathology.

[43]  A. Berchuck,et al.  PTEN/MMAC1 mutations in endometrial cancers. , 1997, Cancer research.

[44]  Kathleen R. Cho,et al.  Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. , 1997, Cancer research.

[45]  P. Cao,et al.  p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. , 1996, Gynecologic oncology.

[46]  K. Isselbacher,et al.  Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[47]  C. Clarke,et al.  Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor. , 1992, Cancer letters.

[48]  M. Inoue,et al.  K-ras activation in premalignant and malignant epithelial lesions of the human uterus. , 1991, Cancer research.

[49]  P. Satyaswaroop,et al.  Designing a schedule of progestin administration in the control of endometrial carcinoma growth in the nude mouse model. , 1990, American journal of obstetrics and gynecology.

[50]  G. Sutton,et al.  Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. , 1988, American journal of obstetrics and gynecology.

[51]  R. Kurman,et al.  The behavior of endometrial hyperplasia. A long‐term study of “untreated” hyperplasia in 170 patients , 1985 .

[52]  J. Kim,et al.  Role of progesterone in endometrial cancer. , 2010, Seminars in reproductive medicine.

[53]  G. Fleming,et al.  Current treatment of metastatic endometrial cancer. , 2009, Cancer control : journal of the Moffitt Cancer Center.

[54]  C. Farquhar,et al.  Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. , 2009, The Cochrane database of systematic reviews.

[55]  A. Wandinger-Ness,et al.  Progesterone receptor isoform identification and subcellular localization in endometrial cancer. , 2005, Gynecologic oncology.

[56]  L. J. Schelven.  Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study , 2004 .

[57]  J. Sorosky,et al.  Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. , 2004, Gynecologic oncology.

[58]  R. Dahiya,et al.  Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. , 2001, Cancer research.

[59]  M. Carey,et al.  A phase II study of leuprolide in advanced/recurrent endometrial cancer. , 1997, Gynecologic oncology.

[60]  M. Sherman,et al.  Endometrial cancer chemoprevention: Implications of diverse pathways of carcinogenesis , 1995, Journal of cellular biochemistry. Supplement.